Medipharm Labs Corp
TSX:LABS

Watchlist Manager
Medipharm Labs Corp Logo
Medipharm Labs Corp
TSX:LABS
Watchlist
Price: 0.075 CAD 7.14% Market Closed
Market Cap: 31.6m CAD

Medipharm Labs Corp
PP&E Net

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Medipharm Labs Corp
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Medipharm Labs Corp
TSX:LABS
PP&E Net
CA$17.9m
CAGR 3-Years
-1%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
Bausch Health Companies Inc
TSX:BHC
PP&E Net
$2B
CAGR 3-Years
10%
CAGR 5-Years
6%
CAGR 10-Years
4%
Canopy Growth Corp
TSX:WEED
PP&E Net
CA$288.8m
CAGR 3-Years
-31%
CAGR 5-Years
-28%
CAGR 10-Years
21%
Sundial Growers Inc
NASDAQ:SNDL
PP&E Net
CA$275.2m
CAGR 3-Years
-3%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
PP&E Net
$147.1m
CAGR 3-Years
31%
CAGR 5-Years
-4%
CAGR 10-Years
59%
K
Knight Therapeutics Inc
TSX:GUD
PP&E Net
CA$21.8m
CAGR 3-Years
-15%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
No Stocks Found

Medipharm Labs Corp
Glance View

Market Cap
31.6m CAD
Industry
Pharmaceuticals

MediPharm Labs Corp. is medicinal cannabis company, which engages in the pharmaceutical grade production of cannabis oil products. The company is headquartered in Barrie, Ontario and currently employs 190 full-time employees. The company went IPO on 2018-02-09. The firm produces purified, pharmaceutical-like cannabis extracts and related derivative products. The firm formulates, processes, packages and distributes cannabis extracts and cannabinoid-based products at its Canadian and Australian facilities for domestic and international markets. The Company, through its subsidiaries is engaged in the sale and distribution of cannabis oil, cannabis extracts, cannabis edibles, cannabis topicals, and derivatives to authorized classes of purchasers, as well as controlled human administration trials for sensory testing of cannabis extracts and derivative products. The company is also engaged in the manufacturing of extracts and tinctures of cannabis and cannabis resin for the purpose of a clinical trial or prescribed as medical cannabis products. The firm's wholly owned subsidiaries include MediPharm Labs Inc. and MediPharm Labs Australia Pty. Ltd.

LABS Intrinsic Value
0.114 CAD
Undervaluation 34%
Intrinsic Value
Price

See Also

What is Medipharm Labs Corp's PP&E Net?
PP&E Net
17.9m CAD

Based on the financial report for Sep 30, 2025, Medipharm Labs Corp's PP&E Net amounts to 17.9m CAD.

What is Medipharm Labs Corp's PP&E Net growth rate?
PP&E Net CAGR 5Y
-17%

Over the last year, the PP&E Net growth was -9%. The average annual PP&E Net growth rates for Medipharm Labs Corp have been -1% over the past three years , -17% over the past five years .

Back to Top